Myeloma Paper of the Day, November 1st, suggested by Robert Orlowski
Robert Orlowski shared a post on X:
“Myeloma Paper of the Day: Integrated functional genomic analysis of tumors assessed for drug sensitivity, clinical variables, cytogenetics, mutational profiles and transcriptomes suggests selinexor-based regimen after dara may give improved survival.”
The Functional Transcriptomic Landscape Informs Therapeutic Strategies in Multiple Myeloma
Authors: Praneeth Reddy Sudalagunta, Rafael R Canevarolo, Mark B Meads, Maria Silva, Xiaohong Zhao, Christopher L Cubitt, Samer S Sansil, Gabriel DeAvila, Raghunandan Reddy Alugubelli, Ryan T Bishop, Alexandre Tungesvik, Qi Zhang, Oliver Hampton, Jamie K Teer, Eric A Welsh, Sean J Yoder, Bijal D Shah, Lori Hazlehurst, Robert A Gatenby, Dane R Van Domelen, Yi Chai, Feng Wang, Andrew DeCastro, Amanda M Bloomer, Erin M Siegel, Conor C Lynch, Daniel M Sullivan, Melissa Alsina, Taiga Nishihori, Jason Brayer, John L Cleveland, William Dalton, Christopher J Walker, Yosef Landesman, Rachid Baz, Ariosto S Silva, Kenneth H Shain.
More posts featuring Robert Orlowski.
Robert Orlowski, M.D., Ph.D., holds multiple positions at The University of Texas MD Anderson Cancer Center, including Chairman, Ad Interim Director of Myeloma, and Professor of Medicine in the Departments of Lymphoma/Myeloma and Experimental Therapeutics within the Division of Cancer Medicine. Additionally, he chairs the SWOG Barlogie/Salmon Myeloma Committee, which is part of the National Clinical Trials Network, dedicated to advancing new therapies and understanding the biology of myeloma.
Dr. Orlowski’s expertise lies in both clinical practice and scientific research, with a particular focus on translating laboratory discoveries into effective treatments for patients. He investigates drug resistance mechanisms in myeloma and seeks to identify predictive biomarkers for treatment response. Notably, his past contributions include leadership roles in developing proteasome inhibitors like bortezomib and carfilzomib, as well as monoclonal antibodies such as daratumumab and elotuzumab.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023